News | Peripheral Artery Disease (PAD) | November 08, 2024

Philips Enrolls First Patient in Clinical Trial for Integrated Single-Device to Treat PAD

Cardiovascular Institute of the South successfully treats first patient in the U.S. using Philips’ laser system, marking a milestone in personalized care for PAD patients

 


Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. Procedures that previously required the use of two different devices can now be performed in a single procedure using a single device, simplifying workflows and procedures and potentially reducing the risk and improving outcomes for patients who might otherwise face multiple complex interventions. 

The Cardiovascular Institute of the South in Louisiana recently completed the first case using the new laser catheter. The care team there successfully treated a 78-year-old male with peripheral vascular disease using the Philips device.

“Developing and driving clinical evidence is crucial to improving care and guiding the adoption of new technologies like the Philips laser atherectomy and lithotripsy system,” said Drs. Craig Walker, Pradeep Nair, and McCall Walker of Cardiovascular Institute of the South in Louisiana. “This trial will provide essential data to demonstrate how this combined approach can optimize procedural efficiency and patient outcomes in treating challenging calcified lesions.”

This first procedure not only marks the launch of the THOR IDE trial, but it also showcases how this new technology, which resulted from Philips’ in-house development capabilities, can ease the patient experience by streamlining complex interventions into a single procedure.

The goal of this pivotal study is to evaluate the safety and efficacy of using this device that integrates laser atherectomy and intravascular lithotripsy in a single device to treat complex, calcified lesions in a single procedure for patients with peripheral artery disease (PAD), restoring blood flow to their legs.

The Philips laser catheter integrates two critical PAD treatments into a single device, significantly simplifying the treatment workflow – atherectomy to remove atherosclerotic plaque from the internal surface of an artery, and intravascular lithotripsy to modify calcium deposits within the artery or disrupt calcium deposits in the artery wall. The innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. Compared to conventional intravascular lithotripsy devices, which require the use of a separate ultrasound catheter to create calcium-disrupting sonic shockwaves, the Philips device uses a pulsed laser to instantly vaporize fluid within the blood vessel to create bubbles that expand and then rapidly collapse, generating the required sonic waves as they do so.  

Prospective, single-arm, multicenter study

The prospective, single-arm, multicenter study will enroll up to 155 patients at up to 30 sites in the U.S. Conducted under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), it will assess the system's safety and effectiveness in achieving procedural success with a low rate of complications.

The study’s primary endpoints include freedom from major adverse events (MAEs) such as mortality, unplanned amputations, and clinically driven target lesion revascularization (CD-TLR) within 30 days (about four and a half weeks) of the procedure, as well as achieving less than or equal to 50% residual stenosis post-procedure. Patients will be followed for 12 months.

“This innovative approach to vessel preparation could improve patient outcomes while minimizing the need for multiple therapies and interventions. That makes this an exciting innovation milestone as we enroll the first patient in this important U.S. clinical trial,” said Dr. Genovese, MD, vascular surgeon and co-principal investigator of the THOR* trial at the Penn Advanced Limb Preservation, Hospital of the University of Pennsylvania. “Integrating atherectomy and intravascular lithotripsy into a single device has the potential to revolutionize the treatment of patients with complex femoropopliteal lesions associated with moderate to severe calcifications.”

The Philips laser atherectomy and intravascular lithotripsy system is currently investigational and not yet commercially available anywhere in the world, including the United States. 


Related Content

News | Peripheral Artery Disease (PAD)

Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...

Home December 03, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
News | Peripheral Artery Disease (PAD)

May 8, 2024 — In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals for the ...

Home May 08, 2024
Home
News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
News | Peripheral Artery Disease (PAD)

October 24, 2023 — Four years ago, following a publication based on the limited data available, the U.S. Food and Drug ...

Home October 24, 2023
Home
News | Peripheral Artery Disease (PAD)

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of ...

Home September 14, 2023
Home
Subscribe Now